Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study.

Abstract

One hundred and twenty patients with chronic idiopathic urticaria, who entered a study at five centres (Sheffield, London, Bristol, Cardiff and Leeds) were treated with therapeutic doses of the H1 antagonist chlorpheniramine for 6 weeks. Histamine H1 non-responders (40 patients) were entered into a double-blind study and received chlorpheniramine plus cimetidine 400 mg q.d.s. (21 patients) or chlorpheniramine plus placebo (19 patients) for a further 8 weeks. The most important response measure was the change from baseline of the total symptom score: an assessment of the number and duration of new weals and degree of itching. There was a statistically significant difference between the average response in the two treatment groups in favour of chlorpheniramine plus cimetidine after 4 and 8 weeks' treatment (P less than 0.05 and P less than 0.01, respectively). No significant side-effects related to treatment were noted.

• Authors: S S Bleehen, S E Thomas, M W Greaves, J Newton, C T Kennedy, F Hindley, R Marks, M Hazell, N R Rowell, G M Fairiss
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 117 Issue 1 Pg. 81-8 (Jul 1987) ISSN: 0007-0963 [Print] England
• PMID: 3307890 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Chlorpheniramine
• Cimetidine

Topics

• Chlorpheniramine (adverse effects, therapeutic use)
• Cimetidine (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Therapy, Combination
• Humans
• Random Allocation
• Skin (pathology)
• Urticaria (drug therapy, pathology)